Sirolimus Current Events | Sirolimus News
|
|
|
Sort By:
Page Views | Date |
Anti-rejection drug may increase risk of diabetes after kidney transplant
For patients undergoing kidney transplantation, treatment with the anti-rejection drug sirolimus may lead to an increased risk of diabetes, reports a study in the July Journal of the American Society of Nephrology (JASN). view more (2008-05-23)
Switching immunosuppressants reduces cancer risk in kidney
Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. view more (2009-11-02)
Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression
A new immunosuppression regimen for heart transplant patients can improve kidney function and prevent transplant coronary artery disease, according to two new Mayo Clinic studies. view more (2007-04-26)
Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression
A new immunosuppression regimen for heart transplant patients can improve kidney function and prevent transplant coronary artery disease, according to two new Mayo Clinic studies. view more (2007-04-27)
Comparison of drug-releasing coronary stents show similar effectiveness
Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary artery lesions, according to a study in the February 22 issue of JAMA. view more (2006-02-22)
Transplant drug sirolimus shrinks tumors, improves lung function
The drug sirolimus, normally used to help transplant patients fight organ rejection, may eventually be used as a less invasive treatment for a tumor called angiomyolipomata in patients with who would otherwise face surgery. view more (2008-01-10)
Comparison of anticoagulants for angioplasty show similar outcomes
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within... view more... (2008-03-31)
Drug may prolong organ life in noncompliant kidney transplant patients
New research from the University of California, San Diego Department of Medicine, Division of Nephrology, shows that the anti-rejection drug sirolimus (brand name Rapamune) may help prolong the clinical benefit of transplanted kidneys and delay rejection, especially in patients who do not regularly take their prescribed medications (are... view more... (2008-06-02)
New type of sirolimus-eluting stent demonstrates superior results
A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss. view more (2009-09-22)
Sirolimus-eluting Coronary Stent is cost effective vs. bypass surgery
An independent analysis of a clinical trial comparing the cost-effectiveness of the CYPHER® Sirolimus-eluting Coronary Stent vs. bypass surgery suggests that treatment with the CYPHER® Stent offers a potential cost-savings over bypass surgery. view more (2005-10-21)
Genetic breakthrough offers promise in tackling kidney tumors
A new study has shown promising results in fighting a severe genetic disorder which can create tumours throughout the body. view more (2008-01-11)
ESC Congress 2003: Advocating the use of drug-eluting stents in all patients with coronary disease
IMPORTANT: This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2003. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology ESC Congress 2003: Drug-eluting stents - a universal panacea Coronary artery disease... view more... (2003-09-02)
ESC Congress 2003: Antibiotic drug, Sirolimus, released from a stent prevents re-narrowing of coronary arteries
IMPORTANT: This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2003. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology ESC Congress 2003: Hot Line II - Acute coronary syndromes / percutaneous coronary... view more... (2003-09-01)
Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
The naturally high levels of leptin in diabetic patients may reduce the effectiveness of drug-eluting stents used to treat heart blockages, but using a chemical that differs from the one commonly used to coat stents could counteract this effect. view more (2008-12-18)
Early reports of thrombosis after insertion of drug-eluting stent (pp 1466, 1519)
Authors of a research letter in this week's issue of THE LANCET highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy. view more (2004-10-20)
Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). view more (2009-09-22)
Study highlights benefits of drug-eluting stents in coronary revascularisation (pp 558, 583)
A pooled analysis of 11 previously published trials provides evidence that drug-eluting stents (DES)-increasingly used in coronary angioplasty-have benefits over bare-metal stents (BMS) by reducing the need for later revascularisation and reducing the risk of cardiac events. However the study did not find that the use of DES reduced the risk of... view more... (2004-08-11)
Drug-eluting stents safe, effective for treatment of chronic total occlusions
A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation... view more... (2009-09-22)
Finding key to cancer drug Gleevec's limitations
University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends. view more (2009-08-05)
New Insights into the Mechanisms of Rapamycin
Rapamycin is a new drug which is being used for preventing organ rejection in kidney transplant patients. Since it suppresses the immune response and has a strong cell killing effect, it is a highly interesting substance for potential use in other disease areas such as cancer, autoimmune diseases, and diabetes mellitus. A recent publication of the... view more... (2004-04-07)
|
|
|
|
Sort By:
Page Views | Date |
|
